News · 26 weeks28-60%
2025-10-262026-04-19
Mix1190d
- Other3(27%)
- Earnings3(27%)
- Insider2(18%)
- SEC Filings2(18%)
- Analyst1(9%)
Latest news
25 items- PRApyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537.
- PRRenuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla., April 1, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion™ and the AYON Body Contouring System™ (AYON), today announced that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category for the second consecutive year. "We're proud to be recognized by NewBeauty again," said Charlie Goodwin, Pres
- INSIDERSenior Vice President Citronowicz Moshe exercised 37,000 shares at a strike of $1.80, increasing direct ownership by 8% to 493,504 units (SEC Form 4)4 - Apyx Medical Corp (0000719135) (Issuer)
- ANALYSTApyx Medical upgraded by BTIG Research with a new price targetBTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00
- SECSEC Form 10-K filed by Apyx Medical Corporation10-K - Apyx Medical Corp (0000719135) (Filer)
- SECApyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial ResultsReported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported
- PRApyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81
- PRApyx Medical Corporation to Participate in The Citizens Life Sciences ConferenceCLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. Charlie Goodwin, the Company's President and Chief Executive Officer, and Matt Hill, the Company's Chief Financial Officer, will participate in a fireside chat on Wednesday, March 11, 2026, at 8:25am ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast h
- INSIDERChief Operating Officer Roman Shawn David exercised 12,000 shares at a strike of $1.80 (SEC Form 4)4 - Apyx Medical Corp (0000719135) (Issuer)
- PRApyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceCLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, Utah. To request a meeting with Apyx, investors should contact their BTIG representatives. About Apyx Medical Corporation: Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people's lives through innovative products, including its Helium
- SECApyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue ResultsCLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Preliminary Fourth Quarter 2025 Revenue Summary: Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year. Surgical Aesthetics revenue is expected to be in the range of approximately $16.6 to $16.8 million, representing an increase of approximately 38% year-over-yea
- SECSEC Form EFFECT filed by Apyx Medical CorporationEFFECT - Apyx Medical Corp (0000719135) (Filer)
- ANALYSTRoth Capital initiated coverage on Apyx Medical with a new price targetRoth Capital initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $6.00
- SECApyx Medical Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South KoreaCLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS). The Company plans to start shipping Apyx One consoles and single-use handpieces to South Korea to fill initial orders starting in the fourth quarter of 2025. The Apyx One console is a multi-functional generator incorporating an advanced 3-in-1 energy system
- SECSEC Form S-3 filed by Apyx Medical CorporationS-3 - Apyx Medical Corp (0000719135) (Filer)
- SECSEC Form 8-K filed by Apyx Medical Corporation8-K - Apyx Medical Corp (0000719135) (Filer)
- SECSEC Form 424B5 filed by Apyx Medical Corporation424B5 - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common StockCLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses. Lucid Capital Markets is acting as the sole book-running manager for the offering. All of the shares of common stock to be sold in the offering will be sold by the Company. In addition, the Comp
- SECSEC Form 424B5 filed by Apyx Medical Corporation424B5 - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Announces Proposed Public Offering of Common StockCLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Lucid Capital Markets is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statemen
- ANALYSTApyx Medical upgraded by Citizens JMPCitizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform
- ANALYSTApyx Medical upgraded by Citizens JMP with a new price targetCitizens JMP upgraded Apyx Medical from Mkt Perform to Mkt Outperform and set a new price target of $8.00